Case report

Pulmonary barotrauma in patient suffering from COVID-19

Maria Ludovica Carerj a,1, Giuseppe M. Bucolo a,1, Silvio Mazziotti a, Alfredo Blandino a, Christian Booz b, Giuseppe Cicero a, Tommaso D'Angelo a,∗

a Section of Diagnostic and Interventional Radiology, Department of Biomedical Sciences and Morphological and Functional Imaging, “G. Martino” University Hospital Messina, Messina, Italy
b Department of Diagnostic and Interventional Radiology, “W. Goethe” University Hospital Frankfurt, Frankfurt am Main, Germany

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Pandemic
Pneumomediastinum
Pneumothorax

ABSTRACT

Pneumothorax and pneumomediastinum are life-threatening conditions especially in critically ill patients. One of the most common situations in which they occur is prolonged invasive and non-invasive mechanical ventilation with high end-expiratory pressure. Probably due to the high number of patients with SARS-CoV-2 respiratory infection being treated with mechanical ventilation, increasing number of pulmonary barotrauma cases have been reported.

1. Introduction

In December 2019, an outbreak of severe acute respiratory syndrome caused by novel coronavirus SARS-CoV-2 has been reported for the first time in Wuhan, China [1]. The rapid global spread of the infection caused a pandemic, as declared by the World Health Organization in March 2020 [1].

Patients with SARS-CoV-2 infection can manifest coronavirus disease (COVID-19), with a clinical evolution that can lead in some cases to pulmonary impairment and hypoxic respiratory failure. This may require patients to undergo mechanical invasive (MIV) or non-invasive ventilation (NIV), which has resulted in high rates of hospitalization and intensive care unit (ICU) admissions (5–37%) [2].

Since COVID-19 outbreak, about 750,000 patients have been hospitalized only in Italy, with ICU admission rate of 21.4% [3]. Moreover, in a cohort study performed on 1591 patients in ICU, 88% required MIV and 11% underwent NIV [4].

We here report a case of a patient affected by COVID-19, who underwent NIV for eight days, and presented a rapid clinical deterioration at ninth day, which was caused by pneumothorax and pneumomediastinum, associated with subcutaneous emphysema.

2. Case report

A 65-year-old man was admitted in the subintensive care unit of our hospital and informed consent form was obtained for undergoing any medical treatment. His SARS-CoV2 reverse transcription polymerase chain reaction (PCR) test was positive from two consecutive nasal swabs. He presented after 7 days of fever, severe cough and progressive dyspnea.

He was obese (BMI 32 kg/m2), with history of hypertension and smoke. At hospital admission, his laboratory tests showed a total white blood cell count of 8500 mm2 [normal range (n.r): 4500–9000 mm2], with neutrophilia of 88% (n.r: 60–70%) and lymphocytopenia of 7% (n.r: 20–35%). His C-reactive protein (CRP) blood levels were elevated (4.10 mg/dl; n.r: 0–0.50 mg/dl). Chest X-ray (CXR) revealed bilateral and peripheral “ground-glass” opacities (GGOs) (Figure 1).

He firstly received low-flow oxygen therapy and started antibiotic and steroid therapy, together with enoxaparin thromboprophylaxis. He gradually presented tachypnea and reduced SpO2 (91%), and was subsequently ventilated with NIV using PSV (pressure support ventilation) mode, with SpO2 improvement (stable between 94-96%).

Nine days after introduction of NIV, the patient had acute deterioration with rapid oxygen desaturation (SpO2 = 88%; PaO2/FiO2<100) and pneumothorax was clinically suspected. Bedside CXR was performed and showed pneumothorax, bilateral consolidations, severe subcutaneous emphysema and suspicion of pneumomediastinum (Figure 2a).

The patient was intubated and underwent chest-CT scan (Figure 2b,c) that depicted multiple and subpleural ground-glass opacities (GGOs) with bilateral parenchymal consolidations. Pneumomediastinum...
pneumomediastinum and massive subcutaneous emphysema were also seen and the patient was transferred to ICU.

Chest drains were positioned to treat pneumothorax, and in the following days the patient underwent different ventilation strategies, to improve his respiratory function, including multiple prone positions.

Two weeks later, follow-up bedside CXR showed resolution of pneumothorax with a widening of the mediastinum and increase of bilateral consolidations, suggestive of respiratory distress syndrome (Figure 3). His arterial blood gas values showed a status of mild respiratory acidosis Hydration with the administration of insulin, and adjustment of ventilation parameters were carried out with the aim to restore blood sugar levels and respiratory acidosi status (Table 1). However, the patient progressively deteriorated and deceased three days later.

3. Discussion

Pneumothorax and pneumomediastinum are life-threatening conditions in critically ill patients, and they are encompassed in the spectrum of pulmonary barotrauma [5].

Patients undergoing mechanical ventilation, may develop complications as pulmonary barotrauma with incidence ranging between 4-15% [6]. Alveolar rupture may occur when the pressure gradient between alveoli and interstitium increases too much; this causes air entering into interstitium and determines perivascular interstitial emphysema [6, 7].

The pressure value at which alveolar rupture occurs is associated with excessive tidal volumes during ventilation and can vary with severity of lung injury [7].

This condition can lead to tensive pneumomediastinum through “Macklin’s phenomenon” that consists in the releasing of alveolar air after alveolar rupture, which tracks along peri-bronchial vascular sheaths into the mediastinum [8, 9, 10].

Sustained lung inflammation may represent the key factor in the etiopathogenesis of pulmonary barotrauma in patients undergoing prolonged NIV [11]. Other risk factors include a peak inspiratory pressure of 40 cm H2O and the use of positive end-expiratory pressure (PEEP) [6]. Diffuse alveolar damage can also cause emphysema-like changes with rupture of dilated cystic airspaces and pneumothorax [7, 12, 13].

Pneumomediastinum and pneumothorax have shown to be negative prognostic factors in intubated patients [8]. In particular, the incidence of pulmonary barotrauma is related to duration of lung inflammation, and its occurrence has proven to increase mortality [7].

Figure 1. Bedside chest X-ray performed at admission in sub-intensive care unit. Typical bilateral and subpleural GGOs are shown bilaterally (asterisks), patient’s condition was stable.

Figure 2. Bedside chest X-ray (a), performed after rapid deterioration of patient’s clinical status, shows bilateral GGOs with peripheral distribution, basal consolidations, and suspected pneumomediastinum (arrowheads). Left pneumothorax (arrows) and diffuse subcutaneous emphysema (asterisks) are also seen. The patient was immediately intubated and admitted to ICU, chest-CT scan performed on the same day (b, c) confirmed the presence of multiple ground-glass opacities with typical subpleural distribution, together with bilateral parenchymal consolidations. Left pneumothorax, pneumomediastinum and subcutaneous emphysema are also shown.
Moreover, positive pressure ventilation in presence of an undrained pneumothorax may lead to tensive pneumothorax or pneumomediastinum. This can determine respiratory and hemodynamic failure, related to cardiac tamponade and large vessel compression, with decreased venous return to heart [6, 8].

CXR and CT are crucial for diagnosis and typical signs of tension include mediastinal shift, displacement of anterior junction line, azygosophageal recess, and flattening of heart [14].

Since SARS-CoV-2 outbreak, increasing cases of pneumothorax and pneumomediastinum in hospitalized COVID-19 patients have been reported [6, 7, 8, 12, 15].

An increased incidence of pulmonary barotrauma has been reported also in patients who underwent mechanical ventilation (NIV/MIV) suffering from another severe acute respiratory syndrome (SARS) [16]. In these patients, higher respiratory rates, lower P/F, and higher PaCO$_2$ together with virus-induced alveolar and airways cell damage showed greater likelihood to develop pulmonary barotrauma [17].

In patients suffering from COVID-19, further investigation and studies with larger patient populations are needed to better clarify the pathogenesis of this unfavorable complication. However, clinicians should be aware of complications such as pneumothorax and pneumomediastinum in patients who undergo either invasive or non-invasive mechanical ventilation, since these conditions need prompt recognition and treatment.

**Figure 3.** Follow-up bedside chest X-ray performed in the ICU, thirteen days after CT scan, show resolution of pneumothorax and pneumomediastinum and demonstrates widening of mediastinum, diffuse interstitial edema, and increase of consolidations, consistent with diffuse alveolar damage and respiratory distress syndrome.

**Table 1.** Laboratory tests at the different time points of hospitalization: admission, during non-invasive mechanical ventilation (NIV), at the diagnosis of pneumothorax (PNX) and pneumomediastinum (PMD), during invasive mechanical ventilation (MIV), and three days before death.

| Lab test       | Normal values | Admission day | During NIV | PNX/PMD day | During MIV | 3 days before death |
|----------------|---------------|--------------|------------|-------------|------------|--------------------|
| White Blood Cells | 4500–9000 mm$^2$ | 8500         | 12000     | 13900       | 29900      | 21800              |
| Neutrophils    | 60–70 %       | 88           | 82         | 85          | 88         | 88                |
| Lymphocytes    | 20–35 %       | 7            | 11         | 10          | 7          | 7                 |
| Hematocrit     | 39–49 %       | 42,2         | 41,7       | 42,8        | 44,1       | 43,4              |
| Platelets      | 150–400 × 10^3/μL | 197         | 246        | 368         | 584        | 466               |
| Glycemia       | 60–110 mg/dL  | 152          | 415        | 176         | 207        | 324               |
| BUN            | 15–50 mg/dL   | 47           | 46         | 104         | 130        | 89                |
| Creatinine     | 0,7–1,4 mg/dL | 0,7          | 0,5        | 0,5         | 1          | 0,6               |
| Bilirubin      | 0,1–1,4 mg/dL | 0,47         | 0,58       | 0,5         | 0,41       | 0,52              |
| Na             | 130–150 mmol/L | 132          | 134        | 138         | 135        | 141               |
| K              | 3,6–5,1 mmol/L | 4,3           | 4,6        | 4,6         | 6,2        | 5,1               |
| CPK            | 55–170 U/L    | 552          | 510        | 62          | 139        | 379               |
| CRP            | 0–0,5 mg/dl   | 4,1          | 3,4        | 16,2        | 13,5       | 19,1              |
| PCT            | <0,05 ng/ml   | 0,11         | 0,06       | 0,06        | 0,94       | 0,91              |
| LDH            | 120–246 U/L   | 1251         | 1173       | 922         | 1113       | 888               |
| ALB            | 35–55 g/L     | 34           | 31,7       | 24          | 22,4       | 24,4              |
| INR            | 0,8–1,1       | 1,05         | 1,01       | 1,09        | 0,98       | 1,06              |
| aPTT           | 30–40 sec     | 34,6         | 33,7       | 23,9        | 28,5       | 30,4              |
| AST            | 5–50 U/L      | 32           | 92         | 50          | 69         | 81                |
| ALT            | 5–50 U/L      | 130          | 219        | 80          | 86         | 67                |
| HB             | 14,4–18 g/dL  | 14,2         | 14         | 13,9        | 13,4       | 13,4              |
| PaO$_2$        | 70–100 mmHg   | 74,6         | 114        | 55          | 98         | 94                |
| FiO$_2$        | 0,2           | 0,7          | 0,55       | 1           | 0,6        |                   |
| P/F            | >350          | 373          | 162        | 99          | 98         | 135               |
| Lactate        | 0,6–1,4 mmol/L | 0,9           | 1,1        | 2,4         | 2,4        | 1,5               |
| HCO$_3^-$      | 22–29 mmol/L  | 23,1         | 22,4       | 23          | 21         | 37                |
| PaCO$_2$       | 38–42 mmHg    | 34,5         | 32,2       | 24          | 79         | 71                |
| pH             | 7,35–7,45     | 7,43         | 7,45       | 7,43        | 7,10       | 7,30              |

BUN, Blood Urea Nitrogen; NA, Sodium; K, Potassium; CPK, creatine phosphokinase; CRP, C-reactive protein; PCT, Procalcitonin; LDH, lactate dehydrogenase; ALB, albumin; INR, International Normalized Ratio; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; ALT, alanine transaminase; HB, hemoglobin; PaO$_2$, oxygen partial arterial pressure; FiO$_2$, fraction of inspired oxygen; P/F PaO$_2$/FiO$_2$ Ratio; HCO$_3^-$, Bicarbonate; PaCO$_2$, Partial Pressure of Carbon Dioxide.
Declarations

Author contribution statement

All authors listed have significantly contributed to the investigation, development and writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

Data associated with this study has been deposited at the electronic archive of the University Hospital of Messina.

Declaration of interests statement

The authors declare the following conflict of interests: Tommaso D’Angelo is an Associate Editor of Heliyon Clinical Research.

Additional information

No additional information is available for this paper.

References

[1] C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506.
[2] A.M. Cattelan, E. Di Meco, M. Trevenzoli, et al., Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study, BMC Infect. Dis. 20 (1) (2020) 934.
[3] P. Immovilli, N. Morelli, E. Antonucci, G. Radaelli, M. Barbera, D. Guidetti, COVID-19 mortality and ICU admission: the Italian experience, Crit. Care 24 (1) (2020) 226.
[4] G. Grasselli, A. Zangrillo, A. Zanella, et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA 323 (16) (2020) 1574.
[5] W. Wang, R. Guo, Y. Zheng, L. Jiang, COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema, J. Trav. Med. 27 (5) (2020) taaz062.
[6] E. Paramasivam, A. Bodenham, Air leaks, pneumothorax, and chest drains, Cont. Educ. Anaesth. Crit. Care Pain 8 (6) (2008) 204–209.
[7] X. Wang, J. Duan, X. Han, et al., High incidence and mortality of pneumothorax in critically ill patients with COVID-19, Heart Lung 50 (1) (2021) 37–43.
[8] A. Waki, V. Rizzo, A. Billa, T. Routledge, A.J. Chambers, Pneumomediastinum following intubation in COVID-19 patients: a case series, Anaesthesia 75 (8) (2020) 1076–1081.
[9] A. Campisi, V. Poletti, A.P. Ciarrocchi, M. Salvi, F. Stella, Tension pneumomediastinum in patients with COVID-19, Thorax 75 (12) (2020) 1130–1131.
[10] L. Flower, J.-P.L. Carter, J. Rosales Lopez, A.M. Henry, Tension pneumothorax in a patient with COVID-19, BMJ Case Rep. 13 (5) (2020), e235861.
[11] A. Pattupara, V. Modi, J. Goldberg, et al., Pulmonary barotrauma during noninvasive ventilation in patients with Covid-19, Chest 158 (4) (2020) A337.
[12] T. Shirai, T. Mitsumura, K. Aoyagi, et al., COVID-19 pneumonia complicated by bilateral pneumothorax: a case report, Respirat. Med. Case Rep. 31 (2020) 101230.
[13] A.D.L. Siho, R.H.L. Wong, A.T.H. Lee, et al., Severe acute respiratory syndrome complicated by spontaneous pneumothorax, Chest 125 (6) (2004) 2345–2351.
[14] C. Benz, T.J. Vogl, U. Joseph Schoepf, et al., Value of minimum intensity projections for chest CT in COVID-19 patients, Eur. J. Radiol. (2020) 109478. Published online December.
[15] G. McGuinness, C. Zhan, N. Rosenberg, et al., Increased incidence of barotrauma in patients with COVID-19 on invasive mechanical ventilation, Radiology 297 (2) (2020) E252–E262.
[16] J.M. Nicholls, L.L. Poon, K.C. Lee, et al., Lung pathology of fatal severe acute respiratory syndrome, Lancet 361 (9371) (2003) 1773–1778.
[17] H.-K. Kao, J.-H. Wang, C.-S. Sung, Y.-C. Huang, T.-C. Lien, Pneumothorax and mortality in the mechanically ventilated SARS patients: a prospective clinical study, Crit. Care 9 (4) (2005) 6.